Indiana Fever, Pacers Sports & Entertainment Tap Salesforce to Scale Fan Engagement with Agentic AI
SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, today announced that the Indiana Fever and its parent organization Pacers Sports & Entertainment (PS&E) are deploying Agentforce, Salesforce's digital labor platform, to autonomously scale deeper, more personalized connections with their rapidly expanding fanbase and augment its marketing and sales teams with agentic AI.
In 2024, the Indiana Fever set records in viewership, game attendance, and digital engagement, selling the most game tickets in franchise history and leading to a 265% increase in attendance from the prior season. To build on their record-setting growth, the Fever sought a way to scale the creation and distribution of personalized marketing and sales content.
With Agentforce, the Fever will fuel targeted, intelligent engagement across multiple touch points while scaling operations through AI automation. Salesforce Data Cloud, which unifies previously siloed data, will create comprehensive fan profiles that include recent Fever ticket purchases, merchandise transactions, and service requests. Using Agentforce in Marketing Cloud, the Fever can then leverage this rich data to autonomously craft individualized email campaigns tailored to each fan's preferences and actions. The system can analyze contact records and automatically generate marketing or sales recommendations using transactional, behavioral, and demographic insights. For instance, Agentforce might alert sales reps about upcoming fan birthdays with suggested discount codes, notify customers when their favorite player's jersey restocks, or promote games featuring preferred matchups — all without manual intervention.
"We are building the most valuable database in professional sports, and this partnership with Salesforce is a significant step in that direction,' said Joey Graziano, EVP, Strategy & New Business Ventures, Pacers Sports & Entertainment. 'Agentforce will help us enhance how we engage with our fanbase by offering personalized recommendations at scale, unlocking new opportunities for the Indiana Fever and the entire PS&E ecosystem."
'The Indiana Fever and PS&E are seizing a pivotal moment, and Salesforce is the ideal partner to help them forge deeper, more meaningful connections with its rapidly expanding fanbase," said Adam Evans, SVP Product, Salesforce. "By harnessing the power of the deeply unified Salesforce Platform, the Fever is setting a new standard for understanding and nurturing fans in the WNBA and in sports writ-large."
What's next
As PS&E's database continues to grow, Data Cloud will help the organization to unify customer data across all properties — including the Indiana Fever, the Indiana Pacers, the Gainbridge Fieldhouse event venue, online stores, multiple POS systems and ticketing platforms, and more. In the future, PS&E also anticipates using Agentforce to help power its fan-centric 'ONE loyalty program,' with the aim of creating a unified app where fans can view, manage, track, and interact with every touch point across all PS&E properties and channels.
More information:
Go deeper on The Indiana Fever's Salesforce Story
Learn more about Agentforce
Read additional customer success stories
About Salesforce
Salesforce helps organizations of any size reimagine their business with AI. Agentforce — the digital labor solution for enterprises — seamlessly integrates with Customer 360 applications, Data Cloud, and Einstein AI to create a limitless workforce, bringing humans and agents together to deliver customer success on a single, trusted platform. Visit www.salesforce.com for more information.
About the Indiana Fever
The Indiana Fever is a professional basketball team in the Women's National Basketball Association (WNBA), based in Indianapolis. Founded in 2000, the team is part of Pacers Sports & Entertainment (PS&E). The Indiana Fever has garnered significant attention and a passionate fanbase, particularly with the addition of standout player Caitlin Clark in 2024. The team plays its home games at Gainbridge Fieldhouse.
About Pacers Sports & Entertainment
Pacers Sports & Entertainment is the corporate identity exemplified by the Indiana Pacers, Indiana Fever, Noblesville Boom, Pacers Foundation, Inc., and Gainbridge Fieldhouse. Its team of inspired and dedicated employees promises to deliver quality entertainment and unparalleled service.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
Yahoo
2 hours ago
- Yahoo
What To Expect From Lennar's (LEN) Q2 Earnings
Homebuilder Lennar (NYSE:LEN) will be announcing earnings results tomorrow after market close. Here's what investors should know. Lennar beat analysts' revenue expectations by 2% last quarter, reporting revenues of $7.63 billion, up 4.4% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates but a miss of analysts' backlog estimates. Is Lennar a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lennar's revenue to decline 5.5% year on year to $8.29 billion, a reversal from the 9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.94 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lennar has missed Wall Street's revenue estimates twice over the last two years. With Lennar being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for industrials stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Lennar is down 2.3% during the same time and is heading into earnings with an average analyst price target of $132.69 (compared to the current share price of $108.64). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
3 hours ago
- Yahoo
Sabrina Ionescu gets 100% real on Caitlin Clark's big performance
The post Sabrina Ionescu gets 100% real on Caitlin Clark's big performance appeared first on ClutchPoints. The Indiana Fever got a huge boost before their big matchup against the New York Liberty on Saturday when it was announced that star guard Caitlin Clark would make her return from a quad injury. And Clark set the tone early with a huge first quarter that carried over throughout the Fever's 102-88 win against the Liberty. Following the game, Liberty star Sabrina Ionescu spoke about Clark's return and her overall performance, as per Myles Ehrlich of Winsidr. Advertisement 'Basketball is a game of runs. . .the same way we go on runs, they do as well, they're a great team,' Ionescu said. 'I think we gave [Caitlin] too many easy ones, she has great range. . .On a personal level, I'm happy to see her out there on the court and feeling good.' Caitlin Clark finished with a team-high 32 points, eight rebounds, nine assists, one steal and two blocked shots in the Fever's win. She shot 55 percent from the field, 50 percent from the three-point line and 60 percent from the free-throw line in a little over 31 minutes of play. On the flip side, Sabrina Ionescu was the game's leading scorer with 34 points in the Liberty's loss. She also added two rebounds, four assists and one steal while shooting 55 percent from the field, 40 percent from the three-point line and 88.9 percent shooting from the free-throw line. Clark had been out since May 24, the Fever's fourth game of the season, due to the quad injury. The Fever went 2-3 in Clark's absence. With the win against the Liberty, the Fever now move to 5-5 on the season. Advertisement Through the first four games of the Fever's season, Clark had been playing just about 35 minutes per game. She was averaging 19.0 points, 6.0 rebounds, 9.3 assists, 1.3 steals and 1.0 blocked shots with splits of 40.3 percent shooting from the field, 31.4 percent shooting from the three-point line and 75 percent shooting from the free-throw line. Related: Natasha Cloud surpasses WNBA legend despite loss to Fever Related: The difficult lessons the Liberty received from 1st loss of season
